Compare Nebius Group NV (NBIS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Novartis AG — how do they compare? Nebius Group NV trades at $210.89 (market cap $46.75B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 6.4× Nebius Group NV's market cap, and Novartis AG pays a 3.02% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | NVS | |
|---|---|---|
Market Cap | $46.75B | $298.18B |
Sector | Technology | Health |
52-Week High | $286.69 | $168.62 |
52-Week Low | $64.06 | $119.31 |
Enterprise Value | $46.94B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $187.97, down 1.01% with a bearish technical signal despite strong analyst support. The stock shows extreme valuation multiples (P/E 71.08, P/S 55.67) while demonstrating explosive revenue growth projections from $530M in 2025 to $878M in 2026. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing, with Q2 2026 results pending. The company faces significant execution risk as it scales AI infrastructure amid substantial capital expenditures.
The investment case hinges on NBIS converting its $1.9B annual run rate and contracted backlog into profitable growth. While analyst consensus remains strongly bullish with a $248.73 price target, high valuation and Michael Burry's short position highlight execution risks. Success depends on managing capex intensity and demonstrating operating leverage in upcoming earnings.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
